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I. PROJECT ID NUMBER, PUBLICATION MORATORIUM INFORMATION, 
PROJECT DESCRIPTION: 
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published. These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects. For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)) and the Nature Precedings HMP summary page. 
 
Project ID: 46327. 
Publication moratorium: One year. 
 
The human microbiota contributes to our normal postnatal development and plays a significant 
role in defining our physiology. To understand the role of microbiota in human health and 
disease, we study the skin microbiome in pilosebaceous units (hair follicles) and its association 
with acne. 
 
Acne is one of the most common skin diseases. Although its etiology still needs to be defined, a 
bacterial factor has been suggested in the development of the disease. In fact, antibiotic therapy 
targeting Propionibacterium acnes has been a mainstay treatment for more than 30 years. 
 
Our preliminary study shows that the microcomedone, a specialized skin compartment where 
acne arises, has a tractable microbiome, with a single dominant species, P. acnes. This system 
offers a unique advantage allowing in-depth analysis of a human microbiome at the subspecies 
level by sequencing. Our preliminary study suggests that the microbiome associated with acne 
offers promise for understanding the correlation between the composition of the microbiome and 
human health and disease. 
 
The goal of the project is to determine whether the microbiota in the pilosebaceous units 
contributes to acne. We plan to investigate the microbiome associated with acne in three 
directions. First, we plan to investigate the strain diversity of P. acnes in a disease cohort and a 
normal cohort and examine whether certain strains of P. acnes are correlated with the disease. 
Second, we plan to investigate the non-P. acnes microbes in microcomedones and disease 
lesions and examine whether they correlate with acne pathogenesis. Third, we will examine the 
interactions between the microbes and the host by transcriptional profiling of both the microbiota 
and the host. 
 
During the first year of this project, two main questions were asked. 1. Are certain strains of P. 
acnes associated with acne, but rarely found in normal individuals? 2. If specific strains are 
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associated with acne, what are the differences in their genetic composition compared to other P. 
acnes strains that are not associated with acne? We collected microcomedone samples from more 
than 100 subjects, including acne patients and normal individuals. Genomic DNA was extracted 
from each sample, and 16S rDNA was amplified using universal primers (8F and 1510R), cloned 
and sequenced using Sanger method. Approximately 384 near full length 16S rDNA sequences 
were obtained for each sample. Some of the microcomedone samples were also cultured under 
anaerobic condition to isolate different P. acnes strains. Sixty-eight isolates were selected for 
whole genome shotgun sequencing using Solexa/Illumina platform. By the end of the first year 
of the project, we completed the sequencing of more than 40,000 16S rDNA clones and 68 
genomes of P. acnes isolates. 
 
II. DATA QUALITY: 
 
Our data quality control follows the guidelines established for the Human Microbiome Project 
(HMP). All the library construction, Sanger sequencing and Solexa/Illumina sequencing were 
performed at the Genome Center at Washington University (GCWU), which is one of the four 
NIH-funded genome sequencing centers for the HMP. 
 
The quality of capillary sequencing data (Sanger sequencing on the AB3730 instrument) at 
GCWU is measured by assessing the failure rate of each individual set of 96 lanes within one full 
run. Within each run the failures are samples with no data or samples that have fewer than 20 
high quality bases. A high quality base is one with a quality score greater than phred Q20. The 
number of such failed samples is noted for each run. Successful runs are those with fewer than 
20% failures, although this number is often set more stringently. In addition, the overall read 
length for all passing samples is measured across many different variables (e.g. high quality 
bases) to make sure that it stays within the standard expected for this platform. The expected 
read length at this time is 700 bases of a quality score greater than phred Q20. 
 
The Solexa/Illumina production pipeline is evaluated by the number of passing reads that contain 
high quality data. The Illumina software on the instrument calculates the number of passing 
reads as well as the number of clusters (a cluster is formed from a single DNA fragment) that 
might produce data. The reports also offer information regarding the phasing or the ability of the 
instrument to stay in step with each base that is called. In addition to this, when possible, the 
error rate is evaluated by evaluation of an internal standard of known sequence or by alignment 
of the experimental sequences to known reference sequences, when available. Successful runs 
are those producing an expected full set of reads with a low error rate. The full set of reads 
depends on the sequencing conditions while error rates are typically < 1%, analogous to phred 
Q20. 
 
III. DATA ANALYSIS AND PUBLICATION PLANS: 
 
Data Analysis Plan 
We are currently analyzing the 16S rDNA data from acne patients and normal individuals to 
investigate whether there are differences at the species level and P. acnes subspecies level 
between the two groups. Bidirectional 16S rDNA reads are assembled and aligned to a core set 
of NAST-formatted sequences using AmosCmp16Spipeline and NAST-iEr from the Microbiome 
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Utilities Portal of the Broad Institute (http://microbiomeutil.sourceforge.net/). Suspected 
chimeras are identified using ChimeraSlayer and Wigeon (Microbiome Utilities Portal of the 
Broad Institute). Sequences with at least 90% bootstrap support for a chimeric breakpoint 
(ChimeraSlayer) or containing a region that varies at more than the 99% quantile of expected 
variation (WigeoN) are removed from further analysis. 
 
For the P. acnes ribotype analysis, the resulting sequences are trimmed to include only positions 
29 to 1483 (numbering based on the E. coli system of nomenclature). Sequences without full 
coverage over this region are excluded from further analysis. Low quality sequences with more 
than 50 bases between positions 79 to 1433 with phred quality scores of less than 15 are also 
excluded. Since the ribotype analysis compares highly similar sequences, the data are extensively 
manually edited. Chromatograms are visually inspected at all bases with a phred quality score < 
30, and appropriate corrections are applied. 
 
For the all species analysis, requirements of full length and high quality sequences are not used 
to screen sequences, since a high quality match is required at the species assignment step. 
Species assignments are transferred from BLASTN top scoring matches to the rRNA16S gold 
database (Microbiome Utilities Portal of the Broad Institute) only for matches with > 1000 
nucleotides aligned at > 97% identity. 
 
To determine the differences in genetic composition between the P. acnes strains found in acne 
and the ones found in normal individuals, we are working on genome assembly, annotation and 
comparison of the 68 P. acnes isolates using the whole genome shotgun sequence data. For 
genome comparison, we are analyzing the core regions, non-core regions and the pan-genome of 
P. acnes. The core regions are identified as sequences that are present in all P. acnes genomes 
and are mapped to the reference genome P. acnes KPA171202 using Nucmer. Single nucleotide 
polymorphisms are identified for each strain. The non-core regions are identified by subtracting 
the core regions from the P. acnes genomes. The pan-genome calculation is based on the method 
described in Tettelin H. et al, 2005. 
 
Publication Plan 
We plan to submit for publication the initial results of the 16S rDNA sequence analysis and the 
P. acnes genome analysis within one year. 
 
IV. DATA RELEASE PLAN: 
 
We will follow the data release and resource sharing policies specified as part of the NIH 
Roadmap HMP, as described on the HMP website at 
http://nihroadmap.nih.gov/hmp/datareleaseguidelines.asp. All types of data generated, including 
clinical data, will be released in accordance with the guiding principles stated for the HMP. In 
addition, we will, when appropriate, collaborate with the DACC to facilitate the standardization, 
transfer, exchange and dissemination of information. 
 
The data release plan will include release of raw sequence data, data from next generation 
sequencing platforms as agreed by the sequence producers and NCBI, genome assemblies and 
their annotations, clinical data, and other metadata associated with all data types. Data of all 
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types (human sequence, clinical data, transcription data, etc.) that contain potentially identifying 
information will be submitted to NCBI’s dbGaP (a controlled access database). Some of these 
types of data will be released only after screening by NCBI. Data release plans specifying how 
those types of data will be verified are developed in consultation with the other funded HMP 
projects to ensure consistency in quality and verification standards. 
 
Genome and Metagenome Sequence Data 
All raw genome and metagenome sequence (which includes 16S rDNA sequence) and next 
generation sequence data that are generated by HMP data production cooperative agreements are 
being submitted to the Trace Archive or to the Short Read Archive at NCBI/NLM/NIH. These 
data will also include information on templates, vectors, and quality values for each sequence. 
 
A minimum metadata set associated with genome and metagenome sequence data will be 
submitted to NCBI along with the sequence data. All sequence data and metadata that are 
potentially identifying of the donor will be deposited in controlled access portion of dbGaP. 
 
Genome, Metagenome Assembly and Annotation 
Genome and metagenome full and partial assemblies and their annotations will be deposited in 
GenBank at NCBI after verification by the center. Deposited metadata associated with genome 
and metagenome assemblies and annotation will be connected to the genome, metagenome 
assemblies and annotation data files. 
 
Clinical Data 
Clinical data will be submitted to the controlled access database dbGaP, consistent with the 
protection of donor privacy. 
 
Finally, the data release plan will be in line with the data release guidelines already developed by 
the International Human Microbiome Consortium (IHMC).  
 
V. CONTACT PERSON: 
 
Dr. Huiying Li, University of California, Los Angeles, huiying@mednet.ucla.edu. 
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